Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel
0.5% applied topically once daily for 29 days versus vehicle control, in subjects with
moderate to severe chronic persistent vascular facial erythema